Teriparatide increases hip & spine BMD, particularly in type I osteogenesis imperfecta
Evaluation of teriparatide treatment in adults with osteogenesis imperfectaJ Clin Invest. 2014 Feb 3;124(2):491-8. doi: 10.1172/JCI71101.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
79 patients with osteogenesis imperfecta (OI) were randomized to receive either teriparatide (recombinant human parathyroid hormone) or a placebo administered subcutaneously daily for 18 months. The purpose of this proof-of-concept study was to determine whether teriparatide increased bone formation and positively affected skeletal mass and strength versus a placebo. The results at 18 months indic...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE